Non Small Cell Lung
Conditions
Brief summary
This study is designed to evaluate the efficacy and safety of Pyrotinib in patients of advanced pre-treated Non-small cell lung cancer With HER2 Mutation. To observe objective response rate (ORR) of pyrotinib in NSCLC With HER2 Mutation. To observe Progression free survival (PFS). To assess the overall survival (OS). A secondary aim is to obtain safety information. To explore the relationship between biomarkers and the toxicity/efficacy of Pyrotinib.
Interventions
DRUGpyrotinib
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. ECOG performance status of 0 to 1. 2. Life expectancy of more than 3 months. 3. At least one measurable lesion exists.(RECIST 1.1). 4. Histologically or cytologic confirmed Non-small cell lung cancer, Phase IIIB or IV according to IASLC 2009. 5. Failed prior therapies.(RECIST 1.1). 6. Confirmed HER2 mutation by Central Laboratory。 7. More than one prior Platinum based chemotherapy for advanced and/or metastatic, or recurrent NSCLC in neoadjuvant or adjuvant chemotherapy. 8. Required laboratory values including following parameters: ANC: ≥ 1.5 x 10\^9/L; Platelet count: ≥ 90 x 10\^9/L; Hemoglobin: ≥ 90 g/L; Total bilirubin: ≤ 1.5 x upper limit of normal (ULN); ALT and AST: ≤2 x ULN or ALT and AST: ≤5x ULN for patients with liver metastasis; BUN and Cr: ≤1.5 x ULN； creatine clearance rate: ≥ 50 mL/min; LVEF: ≥ 50%; QTcF: \< 470 ms for female and \< 450 ms for male. 9. Signed informed consent
Exclusion criteria
1. Previous therapy with other HER2 inhibitors. 2. History of severe hypersensitivity reactions to the excipients of the trial drugs. 3. Have clinically significant cavity effusion,such as pleural effusion、 pericardial effusion or ascites and require clinical intervention 4. Active brain metastases 5. Other malignancy within the past (including primary brain tumor or Leptomeningeal tumor), other than basal cell skin cancer or carcinoma in situ of the cervix 6. Persistence of clinically relevant therapy related toxicities from previous therapy (greater than Common Terminology Criteria for Adverse Event(CTCAE) 4.0 grade 1) 7. Treatment with surgery, chemotherapy, radiotherapy or other target therapy within the past 4 weeks before start of therapy 8. Uncontrolled hypertensin,diabetes. 9. unstable angina, history of myocardial infarction in the past 6 months, congestive heart failure\>NYHA II, serious cardiac arrhythmia 10. Active infection 11. Variety of factors that affect the oral medication (such as unable to swallow, chronic diarrhea, bowel obstruction and other gastrointestinal disorders or abnormalities 12. History of immunodeficiency, including HIV-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation. 13. Subjects had any heart disease, including: (1) angina; (2) requiring medication or clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5) Any heart diseases judged by investigator as unsuitable to participate in the trial. 14. Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test. 15. Known history of neurological or psychiatric disease, including epilepsy or dementia. 16. Treatment in another clinical trial within the past 4 weeks before start of therapy 17. Any of the other conditions of which researchers believe that the patient is not fit to take part in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR) | tumor assessment every 6-9 weeks after the initiation of pyrotinib, up to 24 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and Intensity of Adverse Events | From signing informed consent document until 28 days after the last drug administration | Number of Participants with treatment related Adverse Events as Assessed by CTCAE v4.0 |
| Progression Free Survival (PFS) | up to 24 months | — |
Countries
China
Outcome results
None listed